Tumour mutational burden is overestimated by target cancer gene panels
Background: Tumour mutational burden (TMB) has emerged as a predictive marker for responsiveness to immune checkpoint inhibitors (ICI) in multiple tumour types. It can be calculated from somatic mutations detected from whole exome or targeted panel sequencing data. As mutations are unevenly distribu...
Main Authors: | Hu Fang, Johanna Bertl, Xiaoqiang Zhu, Tai Chung Lam, Song Wu, David J.H. Shih, Jason W.H. Wong |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | Journal of the National Cancer Center |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2667005422000801 |
Similar Items
-
Tumour mutational burden: primary versus metastatic tissue creates systematic bias
by: Desiree Schnidrig, et al.
Published: (2019-12-01) -
Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
by: Antonio Santaniello, et al.
Published: (2019-09-01) -
Bias and inconsistency in the estimation of tumour mutation burden
by: Mohammad A. Makrooni, et al.
Published: (2022-08-01) -
STING signalling compensates for low tumour mutation burden to drive anti-tumour immunityResearch in context
by: Jiayi Tan, et al.
Published: (2024-03-01) -
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
by: Romualdo Barroso-Sousa, et al.
Published: (2023-08-01)